AUIN

Many clones produced on the murine hybridoma platform produce interesting monoclonal antibodies, but have slower cell machinery, thus becoming clones of low proliferation index, and their process is not industrially scalable. This new technology presents a process of exposure to LED light of these clones capable of optimizing the synthesis of immunoglobins without significantly altering cell growth, thus bringing about improvements in the production process and significant reduction in their costs since more clones would be available and exploitable.

The use of this new technology provides the development of new equipment or the improvement of existing equipment for the biopharmaceutical industry and promotes an increase in the production of monoclonal antibodies, thus leading to a reduction in the cost of the final product.